麗珠集團(000513.SZ):目前公司BD戰略方向主要集中在消化道、生殖等優勢領域
格隆匯2月1日丨麗珠集團(000513.SZ)近期在接待機構投資者調研時表示,2023年,公司在BD方面取得階段性進展,先後引進了多款創新產品:消化道領域鉀離子競爭性酸阻滯劑(P-CAB)、心血管領域凝血酶抑制劑,進一步拓展了研發管線,豐富了公司創新藥產品佈局。
目前公司BD的戰略方向主要集中在消化道、生殖、精神神經等優勢領域,同時在腫瘤、代謝領域也在加強關注。公司在中國大陸及中國香港、美國、英國均設有BD辦公室。公司正在全球範圍內加大力度尋找優秀產品,不同的研發階段藥物都在關注,尤其是重點關注臨牀II、III期產品,希望在引進後儘快推動商業化進程,爭取進一步豐富公司的產品管線,實現短期、中期、長期進行合理佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.